Related Experiment Video
Updated: May 20, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Ecological evaluation of executive functions in mild cognitive impairment and Alzheimer disease
Cristiane Garcia da Costa Armentano1, Cláudia S Porto, Ricardo Nitrini
1Behavioral and Cognitive Neurology Unit, Department of Neurology, University of São Paulo School of Medicine, São Paulo, SP, Brazil. cristiane.armentano@superig.com.br
Abstract:
Executive deficits characterize the initial phases of Alzheimer disease (AD) and mild cognitive impairment (MCI), and are clinically correlated to neuropsychiatric symptoms and functional loss. The aim of this study was to determine the accuracy of the Behavioral Assessment of the Dysexecutive Syndrome test (BADS) for comparing the performance between patients with amnestic MCI (aMCI) and mild AD and for detecting early signs of alterations in executive functions. BADS was performed on 60 healthy controls, 20 patients with aMCI, and 40 mild probable AD patients (20 early-onset AD patients and 20 late-onset AD patients). Significant differences in battery performance were found among groups on the BADS subtests Rule Shift Cards, Program of Action, Zoo Map, 6 Modified Elements, and 3 total scores. Early changes in executive functions were detected in both AD (irrespective of age of onset) and aMCI patients. The BADS proved useful for differentiating between these patient groups. Our results confirmed the presence of early alterations in executive functions among aMCI and mild AD patients.
More Related Videos
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
Related Concept Videos
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction
Cognitive Development During Adulthood
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer Disease ll: Pathophysiology